HANSOH PHARMA's Ameile Gains Two New Indications in China's NRDL
Stock Performance: HANSOH PHARMA (03692.HK) experienced a decrease of 0.180 (-0.429%) in its stock price, with short selling amounting to $346.42M and a ratio of 54.641%.
New Drug Indications: The company announced that two new indications for its innovative drug Ameile have been added to the National Reimbursement Drug List (2025 Version), effective January 1, 2026.
Renewal of Existing Drugs: All indications for HANSOH's other innovative drugs, Saint Luolai and Hengmu, have been successfully renewed in the 2025 NRDL.
Implementation Date: The new National Reimbursement Drug List will officially come into effect on January 1, 2026.
Trade with 70% Backtested Accuracy
Analyst Views on 03692
About the author
Nomura Raises HANSOH PHARMA's Target Price to HKD37.87 Following Increased Revenue and Earnings Projections
Company Performance: HANSOH PHARMA expects a 10% growth in both revenue and earnings for FY26, with a projected 27% YoY revenue increase in 2H25 to RMB7.3 billion, driven by a 17% growth in drug sales.
Analyst Forecasts: Nomura has raised its FY25 revenue and earnings forecasts for HANSOH PHARMA by 1% and 4.7% respectively, adjusting for higher collaboration revenue, and has increased the target price from HKD35.5 to HKD37.87 while maintaining a Neutral rating.
UOB Kay Hian Supports ALI HEALTH and PA GOODDOCTOR as AI Innovations and National Policies Propel China's Internet Healthcare Industry
Chinese Internet Healthcare Sector Growth: The sector is evolving with increased AI innovation from tech giants and support from national policies, such as Beijing's online consultation pilot program, despite profitability challenges.
Stock Recommendations: UOB Kay Hian maintains a positive outlook on companies like ALI HEALTH and PA GOODDOCTOR, projecting significant revenue growth driven by AI and synergies with major partners.
Top Picks in Healthcare: UOB Kay Hian's top stock picks include BEONE MEDICINES, INNOVENT BIO, and HANSOH PHARMA, highlighting their potential for growth in the Chinese healthcare market.
Investment Ratings: Various companies in the sector have received investment ratings, with several being rated as "Buy," indicating strong confidence in their future performance.
G Sachs: This Year, China's Healthcare Sector Depends More on Data and Earnings Clarity; Favorable Outlook for CDMO Companies
Healthcare Sector Outlook: Goldman Sachs predicts that the strong trend in China's healthcare sector will continue, with stock trading increasingly focused on companies' execution capabilities and R&D pipelines rather than just licensing expectations.
CDMO Companies Favorable: The broker is optimistic about CDMO companies due to their growth potential and reasonable valuations, upgrading WUXI APPTEC and WUXI XDC to Buy.
Selective Biotech and Pharma Strategy: Goldman Sachs favors biotech and pharmaceutical companies with promising data releases and transaction expectations, highlighting SKB BIO-B, HENLIUS, and HANSOH PHARMA as favorable investments.
Cautious on Medical Services: The broker maintains a neutral stance on the medical devices sector and is cautious about medical services due to cost control measures and weak consumption, downgrading HYGEIA HEALTH and JXR to Neutral/Sell.
HANSOH PHARMA Shares Drop 4.92% Following Announcement of HKD4.68B Convertible Bond Issuance
Stock Performance: Hansoh Pharma's stock opened down 1.04% and traded at HKD38.26, reflecting a decline of 4.92% with significant short selling activity amounting to $44.60 million.
Convertible Bonds Issuance: The company announced a proposed issuance of HKD4.68 billion in zero-coupon convertible bonds due in 2033, with a conversion price set at HKD57.39, representing a 42.62% premium over the previous day's closing price.
HSI Rises by 97 Points; ANTA SPORTS Sees Gains; ZIJIN MINING Jumps 4%
Market Overview: The HSI opened 0.4% higher at 26,863, with the HSCEI and HSTECH also showing slight gains at 9,173 and 5,734, respectively.
Tech Stock Movements: BABA-W launched a new reasoning model and opened up 1%, while other major tech stocks like TENCENT and KUAISHOU-W saw minor increases, whereas JD-SW and BIDU-SW experienced slight declines.
Automotive Sector Updates: BYD and NIO both saw a 1% increase, while XIAOMI-W also grew slightly, indicating positive movement in the automotive market.
Significant Corporate Actions: ANTA SPORTS became Puma's largest shareholder with a 29% stake acquisition, while ZIJIN GOLD INTL surged 12.165% after announcing plans to take over Allied Gold for RMB28 billion.
HANSOH PHARMA Launches $4.68 Billion Zero Coupon Convertible Bonds
Bond Issuance Announcement: Hansoh Pharma announced a proposal to issue zero coupon convertible bonds worth $4.68 billion, maturing in 2033, with an initial conversion price set at $57.39, a 42.62% premium over the previous closing price.
Use of Proceeds: The net proceeds from the bond issuance, estimated at approximately $4.64 billion, will be allocated primarily to drug R&D (65%), construction of new R&D centers and production lines (25%), and general corporate purposes (10%).
Nomura Raises HANSOH PHARMA's Target Price to HKD37.87 Following Increased Revenue and Earnings Projections
Company Performance: HANSOH PHARMA expects a 10% growth in both revenue and earnings for FY26, with a projected 27% YoY revenue increase in 2H25 to RMB7.3 billion, driven by a 17% growth in drug sales.
Analyst Forecasts: Nomura has raised its FY25 revenue and earnings forecasts for HANSOH PHARMA by 1% and 4.7% respectively, adjusting for higher collaboration revenue, and has increased the target price from HKD35.5 to HKD37.87 while maintaining a Neutral rating.
UOB Kay Hian Supports ALI HEALTH and PA GOODDOCTOR as AI Innovations and National Policies Propel China's Internet Healthcare Industry
Chinese Internet Healthcare Sector Growth: The sector is evolving with increased AI innovation from tech giants and support from national policies, such as Beijing's online consultation pilot program, despite profitability challenges.
Stock Recommendations: UOB Kay Hian maintains a positive outlook on companies like ALI HEALTH and PA GOODDOCTOR, projecting significant revenue growth driven by AI and synergies with major partners.
Top Picks in Healthcare: UOB Kay Hian's top stock picks include BEONE MEDICINES, INNOVENT BIO, and HANSOH PHARMA, highlighting their potential for growth in the Chinese healthcare market.
Investment Ratings: Various companies in the sector have received investment ratings, with several being rated as "Buy," indicating strong confidence in their future performance.
G Sachs: This Year, China's Healthcare Sector Depends More on Data and Earnings Clarity; Favorable Outlook for CDMO Companies
Healthcare Sector Outlook: Goldman Sachs predicts that the strong trend in China's healthcare sector will continue, with stock trading increasingly focused on companies' execution capabilities and R&D pipelines rather than just licensing expectations.
CDMO Companies Favorable: The broker is optimistic about CDMO companies due to their growth potential and reasonable valuations, upgrading WUXI APPTEC and WUXI XDC to Buy.
Selective Biotech and Pharma Strategy: Goldman Sachs favors biotech and pharmaceutical companies with promising data releases and transaction expectations, highlighting SKB BIO-B, HENLIUS, and HANSOH PHARMA as favorable investments.
Cautious on Medical Services: The broker maintains a neutral stance on the medical devices sector and is cautious about medical services due to cost control measures and weak consumption, downgrading HYGEIA HEALTH and JXR to Neutral/Sell.
HANSOH PHARMA Shares Drop 4.92% Following Announcement of HKD4.68B Convertible Bond Issuance
Stock Performance: Hansoh Pharma's stock opened down 1.04% and traded at HKD38.26, reflecting a decline of 4.92% with significant short selling activity amounting to $44.60 million.
Convertible Bonds Issuance: The company announced a proposed issuance of HKD4.68 billion in zero-coupon convertible bonds due in 2033, with a conversion price set at HKD57.39, representing a 42.62% premium over the previous day's closing price.
HSI Rises by 97 Points; ANTA SPORTS Sees Gains; ZIJIN MINING Jumps 4%
Market Overview: The HSI opened 0.4% higher at 26,863, with the HSCEI and HSTECH also showing slight gains at 9,173 and 5,734, respectively.
Tech Stock Movements: BABA-W launched a new reasoning model and opened up 1%, while other major tech stocks like TENCENT and KUAISHOU-W saw minor increases, whereas JD-SW and BIDU-SW experienced slight declines.
Automotive Sector Updates: BYD and NIO both saw a 1% increase, while XIAOMI-W also grew slightly, indicating positive movement in the automotive market.
Significant Corporate Actions: ANTA SPORTS became Puma's largest shareholder with a 29% stake acquisition, while ZIJIN GOLD INTL surged 12.165% after announcing plans to take over Allied Gold for RMB28 billion.
HANSOH PHARMA Launches $4.68 Billion Zero Coupon Convertible Bonds
Bond Issuance Announcement: Hansoh Pharma announced a proposal to issue zero coupon convertible bonds worth $4.68 billion, maturing in 2033, with an initial conversion price set at $57.39, a 42.62% premium over the previous closing price.
Use of Proceeds: The net proceeds from the bond issuance, estimated at approximately $4.64 billion, will be allocated primarily to drug R&D (65%), construction of new R&D centers and production lines (25%), and general corporate purposes (10%).
